Results 51 to 60 of about 8,134 (194)

Effect of tolvaptan on acute heart failure with hyponatremia – A randomized, double blind, controlled clinical trial

Indian Heart Journal, 2016
Objectives: To assess the efficacy of tolvaptan in acute heart failure with hyponatremia using a randomized double-blinded placebo-controlled study design. Background: Tolvaptan is a selective vasopressin receptor 2 antagonist.
Elangovan Shanmugam, C.R. Madhu Prabhu Doss, Melvin George, Amrita Jena, Muthukumar Rajaram, Balaji Ramaraj, Karthik Anjaneyan, B. Kanagesh   +7 more
doaj   +1 more source

The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models [PDF]

, 2015
Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity. It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on tumour cells and microvasculature.
Alonso, Daniel Fernando, Garona, Juan, Gomez, Daniel Eduardo, Iannucci, Nancy Beatriz, Orlando, Ulises Daniel, Ortega, Hugo Hector, Pastrian, María Belén, Pifano, Marina, Podesta, Ernesto Jorge, Ripoll, Giselle Vanina   +9 more
core   +1 more source

Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera, Raquel López‐Vilella, Víctor Donoso Trenado, María Peris‐Fernández, Paula Carmona, Amparo Soldevila, Sergi Tormo, Ramón Devesa, María Jesús Montero Hernández, Luis Martínez Dolz, Julio Hernández Jaras, Pilar Sánchez‐Pérez, Luis Almenar‐Bonet   +12 more
wiley   +1 more source

Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists [PDF]

, 2016
Background and Objectives The studies were designed to test the efficacy of two peroxisome proliferator-activated receptor γ (PPARγ) agonists in two rodent models of polycystic kidney disease (PKD).
Blazer-Yost, Bonnie L., Flaig, Stephanie M., Gattone, Vincent H.   +2 more
core   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

Hepatology Research, EarlyView.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano, Taeang Arai, Hidenori Toyoda, Keizo Kato, Joji Tani, Suguru Ogura, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Toshifumi Tada, Akito Nozaki, Atsushi Hiraoka, Kentaro Matsuura, Toru Ishikawa, Naoto Kawabe, Tsunamasa Watanabe, Koichi Takaguchi, Asahiro Morishita, Hironao Okubo, Motoh Iwasa, Hiroki Nishikawa, Yasuhito Tanaka, Masanori Atsukawa   +22 more
wiley   +1 more source

Cardiorenal syndrome [PDF]

, 2015
published_or_final_versio
Pai, MCP
core   +1 more source

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Internal Medicine Journal, EarlyView.
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Mia E. Abdy, Kitty St Pierre, Emily Major, Stephen I. Alexander, Brydee Cashmore, Helen Coolican, Vanessa Cullen, Jessica Dawson, Kelly Lambert, Vincent W. Lee, Amali Mallawaarachi, Gopala Rangan, Judy Savige, Santosh Varughese, David J. Tunnicliffe, Andrew J. Mallett, on behalf of the CARI Guidelines Steering Committee, Emily See, Leanne Brown, Jonathan Craig, Jeffrey Ha, Rathika Krishnasamy, Casey Light, Emmy O'Neill, Thu Nguyen, Hannah Smith, Andrea Viecelli   +26 more
wiley   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Tolvaptan Improves Refractory Ascites and Overall Survival in Cirrhosis: A Meta-Analysis

Current Internal Medicine Research and Practice Surabaya Journal
Introduction: Refractory ascites is a frequent complication associated with liver cirrhosis. Tolvaptan, a V2-receptor antagonist, has shown effectiveness in improving refractory ascites.
Chetan Kalal, Harshad Joshi, Shankar Zanwar, Madhumita Premkumar   +3 more
doaj   +1 more source

Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease [PDF]

, 2019
学位記番号 ...
Ono, Yohei, オノ, ヨウヘイ, 小野, 洋平   +2 more
core